Australia's largest stock trading and investment forum Australia's #1 stock forum

RAC

0.60%

$1.69 race oncology ltd

General Comments / Chat, page-8023

First 8023 Last

Share
Profile

Follow
couldwellb

433 Posts.

212

12/06/23

12:58

Post #: 68244698
Share

Originally posted by Kron00: ↑

Q . What role and responsibilities does a “Product strategy lead” play within oncology at a Major pharmaceutical company such as Novartis?

As a Product Strategy Lead within oncology at a big pharma company like Novartis, your role and responsibilities would typically involve strategic planning and execution related to oncology products.

Here are some key aspects of your role:

1. Product Portfolio Strategy: You would contribute to the development and implementation of the overall product portfolio strategy for oncology. This would include evaluating the competitive landscape, assessing market trends, and identifying opportunities for new product development or portfolio expansion.

2. Market Analysis: You would conduct comprehensive market analysis to understand the needs of patients, physicians, and other stakeholders in the oncology space. This involves gathering and analyzing data on disease prevalence, treatment options, reimbursement dynamics, and pricing trends to inform strategic decision-making.

3. Competitive Intelligence: You would monitor and analyze the activities of competitors in the oncology market, including their product pipelines, clinical trials, and market positioning. This information helps to identify potential threats and opportunities and guides the development of effective strategies.

4. Lifecycle Management: You would play a key role in managing the lifecycle of oncology products, from early-stage development to commercialization and beyond. This involves collaborating with cross-functional teams, such as R&D, medical affairs, marketing, and commercial teams, to ensure alignment and maximize the product's potential.

5. Strategic Planning: You would contribute to the development of long-term strategic plans for the oncology business unit, taking into account factors such as market dynamics, regulatory landscape, and emerging technologies. These plans would outline the objectives, initiatives, and resource allocation required to achieve business goals.

6. Launch Strategy: You would be involved in developing launch strategies for new oncology products, considering aspects such as market positioning, pricing, market access, and promotional activities. Collaborating with marketing and commercial teams, you would help create compelling value propositions and ensure effective communication of product benefits.

7. Cross-functional Collaboration: As a Product Strategy Lead, you would collaborate closely with various internal stakeholders, including R&D, clinical development, regulatory affairs, medical affairs, commercial, and finance teams. This collaboration ensures alignment and effective execution of product strategies across functions.

8. External Engagement: You may also engage with external stakeholders, including healthcare professionals, patient advocacy groups, and key opinion leaders in the oncology field. This helps to gain insights, gather feedback, and build relationships that support product strategy and development.

Overall, as a Product Strategy Lead within oncology at a big pharma company like Novartis, your responsibilities would revolve around shaping the strategic direction of oncology products, ensuring their successful commercialization, and maximizing their impact on patient care.

- “Damian, Great to connect Marilina, love your passion”
- Marilina, Back at you! So much to do, as we embark on this journey together”

CEO - ex novartis
Hiring current novartis, BMS, Celgene etc
Connecting with multiple current novartis
Novartis itself posting about tackling breast cancer
10 + external clinical advisors to guide design, strategy, and path to commercialisation
USA Product strategy lead “Embark on this journey together”
USA centric valuation on breast cancer
DCB “it will all make sense in July/Aug”

Meh, could be nothing..

You’d have to be very game to be letting go of shares right now.

Good luck to those that are, i think you’ll need it when we go into a trading halt.

Expand

If nothing else, Marilina and Mike are both heavy players in their fields at Novartis and more than aware RAC exist and is looking at entering the ‘big boy pants’ arena.

Hopefully we’ve lit up more than one screen as we’ve come out from ‘under the radar’.

RAC Price at posting: $1.42 Sentiment: Buy Disclosure: Held
54 Upvote

2 Great analysis

Reply

Top Stories

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

VUL

Vulcan appoints investment bank and M&A veteran to board

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

There are more pages in this discussion • 3,459 more messages in this thread...

First 8023 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.69		Change 0.010(0.60%)		Mkt cap ! $287.1M

Open	High	Low	Value	Volume
$1.69	$1.70	$1.65	$89.01K	53.2K

Buyers (Bids)

No.	Vol.	Price($)
1	2342	$1.69

Sellers (Offers)

Price($)	Vol.	No.
$1.70	5	1

View Market Depth

No.	Vol.	Price($)
1	2342	1.685
1	3664	1.680
1	5077	1.660
1	1265	1.650
1	612	1.635

Price($)	Vol.	No.
1.695	5	1
1.700	11000	1
1.730	2399	1
1.750	952	2
1.775	1328	1

Last trade - 16.10pm 13/09/2024 (20 minute delay)

RAC (ASX) Chart

General Comments / Chat, page-8023

Utah authorities sign off on Anson's lithium extraction plans at Green River

Vulcan appoints investment bank and M&A veteran to board

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

General Comments / Chat, page-8023

Top Stories

Utah authorities sign off on Anson's lithium extraction plans at Green River

Vulcan appoints investment bank and M&A veteran to board

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News